Brenipatide (LY-3537031) is an investigational once-monthly subcutaneous dual GLP-1 and GIP receptor agonist developed by Eli Lilly and Company. Unlike metabolic-focused sister peptides, it is specifically optimized for central nervous system and psychiatric indications, currently in Phase 3 trials for alcohol use disorder and bipolar disorder. [
1,
2]
Mechanism and Design
- Dual agonist targeting GLP-1 and GIP receptors simultaneously.
- Engineered with a backbone modification providing an extended half-life for once-monthly dosing.
- Optimized for brain and reward-circuitry penetration rather than primary weight loss. [1, 2]
Current Clinical Trials
- Phase 3: Alcohol use disorder, bipolar disorder, and major depressive disorder.
- Phase 2: Asthma, schizophrenia, and smoking cessation relapse prevention.
- Phase 1: Obesity, metabolic disorders, and liver conditions. [1]
If you are looking for specific trial enrollment details or safety data for
brenipatide, please let me know which condition you are interested in.
Click to expand...